P. Morange

A. Evans, D. Arveiler, G. Luc, 2009, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

Association of impaired renal function with venous thrombosis: A genetic risk score approach.

D. Trégouët, S. Hadjadj, M. Germain, 2017, Thrombosis research.

Genomic and Transcriptomic Association Studies Identify 16 Novel Susceptibility Loci for Venous Thromboembolism.

Sebastian M. Armasu, Andrew D. Johnson, James W. MacDonald, 2019, Blood.

PDGFB, a new candidate plasma biomarker for venous thromboembolism: results from the VEREMA affinity proteomics study.

D. Trégouët, M. Uhlén, J. Odeberg, 2016, Blood.

Impact on venous thrombosis risk of newly discovered gene variants associated with FVIII and VWF plasma levels

D. Trégouët, P. Morange, J. Emmerich, 2011, Journal of thrombosis and haemostasis : JTH.

A multi‐stage multi‐design strategy provides strong evidence that the BAI3 locus is associated with early‐onset venous thromboembolism

S. Heath, D. Tregouet, M. Lathrop, 2010, Journal of thrombosis and haemostasis : JTH.

Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predictors of non response.

P. Morange, M. Alessi, T. Cuisset, 2009, Thrombosis research.

Assessing the causal relationship between obesity and venous thromboembolism through a Mendelian Randomization study

P. Ridker, D. Chasman, F. Grodstein, 2017, Human Genetics.

Elevated plasma Complement Factor H Regulating Protein 5 is associated with venous thromboembolism and COVID-19 severity

T. Renné, D. Tregouet, J. Odeberg, 2022, medRxiv.

Diet Modulates Endogenous Thrombin Generation, A Biological Estimate of Thrombosis Risk, Independently of the Metabolic Status

S. Tanguy, P. Morange, M. Poggi, 2012, Arteriosclerosis, thrombosis, and vascular biology.

Prothrombin G20210A carriers the genetic mutation and a history of venous thrombosis contributes to thrombin generation independently of factor II plasma levels

P. Morange, J. Gris, M. Alessi, 2010, Journal of thrombosis and haemostasis : JTH.

An ultra-sensitive, ultra-fast whole blood monocyte CD169 assay for COVID-19 screening

P. Morange, J. Mege, M. Million, 2020, medRxiv.

Assessment of epicardial fat volume and myocardial triglyceride content in severely obese subjects: relationship to metabolic profile, cardiac function and visceral fat

K. Clément, P. Morange, M. Alessi, 2012, International Journal of Obesity.

PAI-1, Obesity, and Insulin Resistance

P. Morange, M. Alessi, I. Juhan-vague, 1999 .

The A -844G polymorphism in the PAI-1 gene is associated with a higher risk of venous thrombosis in factor V Leiden carriers.

D. Trégouët, P. Morange, M. Alessi, 2000, Arteriosclerosis, thrombosis, and vascular biology.

Impaired adhesion of neutrophils expressing Slc44a2/HNA-3b to VWF protects against NETosis under venous shear rate.

P. Morange, P. Legendre, P. Lenting, 2021, Blood.

The Assistance Publique Hôpitaux de Marseille’s Biobank

P. Morange, D. Figarella-Branger, B. Lacarelle, 2020 .

An artificial neural network approach integrating plasma proteomics and 1 genetic data identifies PLXNA 4 as a new susceptibility locus for 2 pulmonary embolism

Manal, Louisa, J. Odeberg, 2020 .

A Genome Wide Association Study on plasma FV levels identified PLXDC2 as a new modifier of the coagulation process

D. Trégouët, P. Morange, P. Eriksson, 2019, Journal of thrombosis and haemostasis : JTH.

The missing heritability of venous thrombosis: what about factor V Leiden heterogeneity?

P. Morange, G. Thomas, P. Fautrad, 2018, Journal of thrombosis and haemostasis : JTH.

Is there still room for additional common susceptibility alleles for venous thromboembolism?

D. Chasman, P. Reitsma, D. Trégouët, 2016, Journal of thrombosis and haemostasis : JTH.

Sex-specific effect of CPB2 Ala147Thr but not Thr325Ile variants on the risk of venous thrombosis: A comprehensive meta-analysis

Michael D. Wilson, D. Trégouët, P. Morange, 2017, PloS one.

Plasma PAI-1 Levels Are More Strongly Related to Liver Steatosis Than to Adipose Tissue Accumulation

P. Morange, D. Bastelica, M. Alessi, 2003, Arteriosclerosis, thrombosis, and vascular biology.

Plasma Thrombin-Activatable Fibrinolysis Inhibitor Antigen Concentration and Genotype in Relation to Myocardial Infarction in the North and South of Europe

M. Margaglione, S. Humphries, E. Hawe, 2002, Arteriosclerosis, thrombosis, and vascular biology.

Plasma TAFI Antigen Variations in Healthy Subjects

P. Morange, P. Chetaille, I. Juhan-vague, 2000, Thrombosis and Haemostasis.

Thrombin-Activatable Fibrinolysis Inhibitor Antigen Levels and Cardiovascular Risk Factors

P. Morange, M. Alessi, I. Juhan-vague, 2000, Arteriosclerosis, thrombosis, and vascular biology.

CYP2C19*2 and *17 alleles have a significant impact on platelet response and bleeding risk in patients treated with prasugrel after acute coronary syndrome.

P. Morange, M. Alessi, T. Cuisset, 2012, JACC. Cardiovascular interventions.

Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study

P. Morange, M. Alessi, G. Bonnet, 2017, European heart journal.

Lack of effect of chronic kidney disease on clopidogrel response with high loading and maintenance doses of clopidogrel after Acute Coronary Syndrome.

P. Morange, M. Alessi, T. Cuisset, 2010, Thrombosis research.

Thrombose et contraception estroprogestative : mise au point du groupe de travail pluridisciplinaire CNGOF-FNCGM-GEHT-SFMV

P. Morange, C. Biron, N. Chabbert-Buffet, 2013 .

[DVT and combined oral contraceptives: update of the pluridisciplinary CNGOF-FNCGM-GEHT-SFMV group].

P. Morange, C. Biron, N. Chabbert-Buffet, 2013, Journal de gynecologie, obstetrique et biologie de la reproduction.

PAI-1 produced ex vivo by human adipose tissue is relevant to PAI-1 blood level.

P. Morange, G. Magalon, I. Juhan-vague, 1999, Arteriosclerosis, thrombosis, and vascular biology.

Homocysteine levels associate with subtle changes in leukocyte DNA methylation: an epigenome-wide analysis.

A. Uitterlinden, J. V. van Meurs, L. Milani, 2017, Epigenomics.

Relationship of Plasminogen Activator Inhibitor-1 Levels following Thrombolytic Therapy with rt-PA as Compared to Streptokinase and Patency of Infarct Related Coronary Artery

S. Lévy, P. Morange, M. Alessi, 1999, Thrombosis and Haemostasis.

Ultrasound arterial anomalies in patients exposed to nilotinib therapy for chronic myeloid leukemia.

P. Morange, P. Suchon, D. Brunet, 2021, Journal de medecine vasculaire.

The EHA Research Roadmap: Blood Coagulation and Hemostatic Disorders

T. van der Poll, D. Trégouët, P. Morange, 2021, HemaSphere.

Impact of obesity and the metabolic syndrome on response to clopidogrel or prasugrel and bleeding risk in patients treated after coronary stenting.

A. Loundou, P. Morange, M. Alessi, 2014, The American journal of cardiology.

Genome-Wide Investigation of DNA Methylation Marks Associated with FV Leiden Mutation

T. Paton, D. Trégouët, M. Germain, 2014, PloS one.

Genetic Polymorphisms and Coronary Artery Disease in the South of France

L. Tiret, P. Morange, O. Poirier, 2000, Thrombosis and Haemostasis.

Association Between Factor VII Polymorphisms and Blood Pressure: The Stanislas Cohort

P. Morange, S. Visvikis-Siest, C. Sass, 2004, Hypertension.

Paraoxonase-1 and clopidogrel efficacy

P. Morange, M. Alessi, T. Cuisset, 2011, Nature Medicine.

Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study.

P. Morange, M. Alessi, T. Cuisset, 2009, Journal of the American College of Cardiology.

Prasugrel monitoring and bleeding in real world patients.

P. Morange, G. Montalescot, M. Kerneis, 2013, The American journal of cardiology.

Effect of CYP2C19*2 and *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications.

W. Cohen, P. Morange, M. Alessi, 2013, The American journal of cardiology.

Apolipoprotein(a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism.

P. Tsao, D. Gudbjartsson, U. Thorsteinsdóttir, 2012, Journal of the American College of Cardiology.

Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin.

P. Morange, Y. Gruel, E. de Maistre, 2006, Blood.

Clinical validation of immunoassay HemosIL® AcuStar HIT-IgG (PF4-H) in the diagnosis of Heparin-induced thrombocytopenia

A. Loundou, P. Morange, L. Camoin-Jau, 2021, Journal of Thrombosis and Thrombolysis.

Argatroban in the management of heparin-induced thrombocytopenia: a multicenter clinical trial

P. Morange, J. Morel, C. Biron-Andréani, 2015, Critical Care.

High prevalence of mutations in perilipin 1 in patients with precocious acute coronary syndrome.

A. Loundou, P. Morange, A. Blanchard, 2019, Atherosclerosis.

Usefulness of high clopidogrel maintenance dose according to CYP2C19 genotypes in clopidogrel low responders undergoing coronary stenting for non ST elevation acute coronary syndrome.

W. Cohen, P. Morange, M. Alessi, 2011, The American journal of cardiology.

Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment?

P. Morange, M. Alessi, G. Cayla, 2009, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[Antiphospholipids antibodies and hemodialysis: a frequent association linked to arteriovenous fistula thrombosis].

P. Morange, C. Frère, N. Jourde-Chiche, 2015, Nephrologie & therapeutique.

Common Risk Factors Add to Inherited Thrombophilia to Predict Venous Thromboembolism Risk in Families

D. Trégouët, P. Morange, M. Alessi, 2019, TH Open.

A follow-up study of a genome-wide association scan identifies a susceptibility locus for venous thrombosis on chromosome 6p24.1.

S. Heath, F. Cambien, S. Blankenberg, 2010, American journal of human genetics.

A 36 G of the tumor necrosis factor receptor 1 gene is associated with PAI-1 levels in obese women

P. Morange, M. Poggi, D. Bastelica, 2018 .

Association of vitronectin and plasminogen activator inhibitor-1 levels with the risk of metabolic syndrome and type 2 diabetes mellitus. Results from the D.E.S.I.R. prospective cohort.

D. Tregouet, B. Balkau, P. Morange, 2011, Thrombosis and haemostasis.

High prevalence of laminopathies among patients with metabolic syndrome.

D. Tregouet, P. Morange, N. Lévy, 2011, Human molecular genetics.

Nutritionally Induced Obesity Is Attenuated in Transgenic Mice Overexpressing Plasminogen Activator Inhibitor-1

P. Morange, M. Alessi, H. Lijnen, 2003, Arteriosclerosis, thrombosis, and vascular biology.

Stromal Cells Are the Main Plasminogen Activator Inhibitor‐1‐Producing Cells in Human Fat: Evidence of Differences Between Visceral and Subcutaneous Deposits

P. Morange, D. Bastelica, M. Alessi, 2002, Arteriosclerosis, thrombosis, and vascular biology.

Nutritionally Induced Obesity Is Attenuated in Transgenic Mice Overexpressing Nutritionally Induced Obesity Is Attenuated in Transgenic Mice Overexpressing Plasminogen Activator Inhibitor-1 Methods Generation and Characterization of Transgenic Mice Diet Model Blood Collection and Tissue Preparation

P. Morange, R. Lijnen, D. Collen, 2022 .

Influence of PAI-1 on adipose tissue growth and metabolic parameters in a murine model of diet-induced obesity.

P. Morange, D. Collen, M. Alessi, 2000, Arteriosclerosis, thrombosis, and vascular biology.

Glucocorticoids and insulin promote plasminogen activator inhibitor 1 production by human adipose tissue.

P. Morange, H. Lijnen, P. Vague, 1999, Diabetes.

and indices of obesity in aboriginal Canadians modulates plasma leptin LMNA Genetic variation in

D. Trégouët, P. Morange, R. Hegele, 2015 .

Rapid Detection of Factor XIII Val34Leu by Allele Specific PCR

P. Morange, I. Juhan-vague, M. Alessi, 1999, Thrombosis and Haemostasis.

Genetic associations for activated partial thromboplastin time and prothrombin time, their gene expression profiles, and risk of coronary artery disease.

Yoav Ben-Shlomo, Eric Boerwinkle, Nilesh J Samani, 2012, American journal of human genetics.

Maximizing the power of principal-component analysis of correlated phenotypes in genome-wide association studies.

P. Kraft, D. Trégouët, Nicolas Greliche, 2013, American journal of human genetics.

Relation between the antithrombin Cambridge II mutation, the risk of venous thrombosis, and the endogenous thrombin generation

P. Morange, M. Alessi, N. Saut, 2008, Journal of thrombosis and haemostasis : JTH.

Formyl Peptide Receptor 2 Plays a Deleterious Role During Influenza A Virus Infections.

P. Morange, Sergey O Tcherniuk, M. Si-Tahar, 2016, The Journal of infectious diseases.

Risk assessment of venous thrombosis in families with known hereditary thrombophilia: the MARseilles-NImes prediction model.

D. Trégouët, W. Cohen, P. Morange, 2014, Journal of thrombosis and haemostasis : JTH.

Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (predictor of bleedings with antiplatelet drugs).

A. Loundou, P. Morange, M. Alessi, 2013, JACC: Cardiovascular Interventions.

Comparison between initial and chronic response to clopidogrel therapy after coronary stenting for acute coronary syndrome and influence on clinical outcomes.

P. Morange, M. Alessi, T. Cuisset, 2012, American heart journal.

Comparison of platelet reactivity and clopidogrel response in patients ≤ 75 Years Versus > 75 years undergoing percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome.

P. Morange, M. Alessi, T. Cuisset, 2011, The American journal of cardiology.

Comparison of rosuvastatin and atorvastatin on clopidogrel response and lipidic and inflammatory parameters after coronary stenting for acute coronary syndrome: the prospective, randomized OSCAR study (optimal statin therapy with clopidogrel after coronary revascularisation).

P. Morange, M. Alessi, T. Cuisset, 2010, Thrombosis research.

Effect of increased aspirin dose after stenting in association with ClOpidogrel: the FIASCO randomized study.

P. Morange, T. Cuisset, J. Bonnet, 2009, Thrombosis research.

Aspirin noncompliance is the major cause of "aspirin resistance" in patients undergoing coronary stenting.

P. Morange, M. Alessi, T. Cuisset, 2009, American heart journal.

ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome

P. Morange, M. Alessi, T. Cuisset, 2007, Thrombosis and Haemostasis.

Prasugrel versus ticagrelor in acute coronary syndrome: a randomized comparison.

P. Morange, M. Alessi, G. Bonnet, 2013, International journal of cardiology.

Effectiveness of switching 'hyper responders' from Prasugrel to Clopidogrel after acute coronary syndrome: the POBA (Predictor of Bleeding with Antiplatelet drugs) SWITCH study.

P. Morange, M. Alessi, G. Bonnet, 2013, International journal of cardiology.

Predictors of long-term high on-treatment platelet reactivity in clopidogrel-treated patients undergoing coronary stenting for acute coronary syndrome.

P. Morange, M. Alessi, T. Cuisset, 2013, International journal of cardiology.

Prognostic value of plasma tissue factor and tissue factor pathway inhibitor for cardiovascular death in patients with coronary artery disease: the AtheroGene study

R. Schnabel, S. Blankenberg, L. Tiret, 2007, Journal of thrombosis and haemostasis : JTH.

ABO Blood Group and von Willebrand Factor Levels Partially Explained the Incomplete Penetrance of Congenital Thrombophilia

D. Tregouet, W. Cohen, P. Morange, 2012, Arteriosclerosis, thrombosis, and vascular biology.

Ethnicity and Haemostasis: Challenge in the genomics era

P. Morange, M. Ibrahim-Kosta, 2020, Journal of thrombosis and haemostasis : JTH.

Association of soluble endothelial protein C receptor plasma levels and PROCR rs867186 with cardiovascular risk factors and cardiovascular events in coronary artery disease patients: The Athero Gene Study

R. Schnabel, D. Tregouet, S. Blankenberg, 2012, BMC Medical Genetics.

DNA methylation and body-mass index: a genome-wide analysis

C. Gieger, M. Waldenberger, T. Spector, 2014, The Lancet.

Hypofibrinolysis and increased PAI-1 are linked to atherothrombosis via insulin resistance and obesity.

P. Morange, I. Juhan-vague, M. Alessi, 2000, Annals of medicine.

Clopidogrel response: head-to-head comparison of different platelet assays to identify clopidogrel non responder patients after coronary stenting.

P. Morange, M. Alessi, T. Cuisset, 2010, Archives of cardiovascular diseases.

Edinburgh Research Explorer Genetic Associations for Activated Partial Thromboplastin Time and Prothrombin Time, their Gene Expression Profiles, and Risk of Coronary Artery Disease

J. Gallacher, P. Visscher, I. Deary, 2018 .

Prevalence and epitope specificity of non-neutralising antibodies in a large cohort of haemophilia A patients without inhibitors

P. Morange, C. Combescure, C. Granier, 2011, Thrombosis and Haemostasis.

Benefit of Switching Dual Antiplatelet Therapy After Acute Coronary Syndrome According to On-Treatment Platelet Reactivity: The TOPIC-VASP Pre-Specified Analysis of the TOPIC Randomized Study.

P. Morange, M. Alessi, G. Bonnet, 2017, JACC. Cardiovascular interventions.

A037 Impact of the CYP2C19*17 allele on platelet response to clopidogrel in patients suffering from non–st elevation acute coronary syndrome

P. Morange, J. Hulot, M. Alessi, 2009 .

A 037 IMPACT OF THE CYP 2 C 19 * 17 ALLELE ON PLATELET RESPONSE TO CLOPIDOGREL IN PATIENTS SUFFERING FROM NON — ST ELEVATION ACUTE CORONARY SYNDROME

P. Morange, J. Hulot, M. Alessi, 2009 .

Bene ﬁ t of Switching Dual Antiplatelet Therapy After Acute Coronary Syndrome According to On-Treatment Platelet Reactivity

P. Morange, M. Alessi, G. Bonnet, 2017 .

Activated thrombin activatable fibrinolysis inhibitor levels are associated with the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study

R. Schnabel, D. Tregouet, S. Blankenberg, 2009, Journal of thrombosis and haemostasis : JTH.

Antithrombotic efficacy of bivalirudin compared to unfractionated heparin during percutaneous coronary intervention for acute coronary syndrome

P. Morange, R. Guieu, G. Lemesle, 2019, Platelets.

Long-read sequencing resolves structural variants in SERPINC1 causing antithrombin deficiency and identifies a complex rearrangement and a retrotransposon insertion not characterized by routine diagnostic methods

Nicholas S. Gleadall, W. Ouwehand, P. Morange, 2020, bioRxiv.

Screening for identified and unidentified protein C pathway defects by the Agkistrodon contortrix venom test in consecutive patients.

P. Morange, I. Juhan-vague, M. Barthet, 1999, American journal of clinical pathology.

Multilocus Genetic Risk Scores for Venous Thromboembolism Risk Assessment

D. Trégouët, P. Morange, J. Vila, 2014, Journal of the American Heart Association.

Weak and non‐independent association between plasma TAFI antigen levels and the insulin resistance syndrome

P. Morange, M. Alessi, C. Frère, 2003, Journal of thrombosis and haemostasis : JTH.

High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes

P. Morange, M. Alessi, T. Cuisset, 2007, Thrombosis and Haemostasis.

Management of bleeding risk in patients who receive anticoagulant therapy for venous thromboembolism: Communication from the ISTH SSC Subcommittee on Predictive and Diagnostic Variables in Thrombotic Disease

P. Morange, J. Hansen, F. Klok, 2022, Journal of thrombosis and haemostasis : JTH.

A systematic review of biomarkers among hospitalized patients with COVID‐19 predictive of venous thromboembolism: A communication from the Predictive and Diagnostic Variables Scientific and Standardization Committee of the ISTH

P. Morange, J. Hansen, F. Klok, 2022, Research and Practice in Thrombosis and Haemostasis.

Plasma Levels of Free and Total TFPI, Relationship with Cardiovascular Risk Factors and Endothelial Cell Markers

P. Morange, M. Charles, I. Juhan-vague, 2001, Thrombosis and Haemostasis.

Heparin‐induced thrombocytopenia: Construction of a pretest diagnostic score derived from the analysis of a prospective multinational database, with internal validation

P. Morange, Y. Gruel, P. Nguyên, 2021, Journal of thrombosis and haemostasis : JTH.

[Risk factors for thromboembolic disease in young women-the role of hormones].

P. Morange, C. Tromeur, L. Bertoletti, 2019, Revue des maladies respiratoires.

Genome-wide association study of a semicontinuous trait: Illustration of the impact of the modeling strategy through the study of Neutrophil Extracellular Traps levels

H. Jacqmin-Gadda, P. Morange, C. Proust, 2022, medRxiv.

Prevention of venous thromboembolism and haemostasis monitoring in patients with COVID-19: Updated proposals (April 2021)

P. Morange, S. Susen, S. Laporte, 2021, Anaesthesia Critical Care & Pain Medicine.

High residual platelet reactivity and thrombotic events.

P. Morange, M. Alessi, T. Cuisset, 2011, JAMA.

Reply to Chen and Vitetta.

P. Morange, D. Olive, J. Mege, 2021, The Journal of infectious diseases.

Body mass index has no impact on platelet inhibition induced by ticagrelor after acute coronary syndrome, conversely to prasugrel.

P. Morange, M. Alessi, G. Bonnet, 2014, International journal of cardiology.

Impact of High-Dose Prophylactic Anticoagulation in Critically Ill Patients With COVID-19 Pneumonia

P. Morange, S. Susen, S. Laporte, 2021, Chest.

The aminosterol Claramine inhibits β-secretase 1–mediated insulin receptor cleavage

P. Morange, R. Govers, J. Brunel, 2021, The Journal of biological chemistry.

Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients.

P. Morange, M. Alessi, T. Cuisset, 2009, The American journal of cardiology.

Fixed-dose aspirin-clopidogrel combination enhances compliance to aspirin after acute coronary syndrome.

P. Morange, M. Alessi, G. Bonnet, 2014, International journal of cardiology.

Single or triple positivity for antiphospholipid antibodies in “carriers” or symptomatic patients: Untangling the knot

P. Morange, J. Mege, N. Resseguier, 2021, Journal of thrombosis and haemostasis : JTH.

Effectiveness of switching 'low responders' to prasugrel to ticagrelor after acute coronary syndrome.

P. Morange, M. Alessi, G. Bonnet, 2014, International Journal of Cardiology.

Descriptive study of the general practitioners' perception of direct oral anticoagulants and the risk of genital bleeding in women of childbearing age.

P. Morange, P. Suchon, D. Brunet, 2020, Journal de medecine vasculaire.

Acquired Protein S Deficiency, Likely due to Anti-PS Autoantibodies, following a Thrombotic Event in a Patient with a Systemic Lupus erythematosus

P. Morange, M. Alessi, J. Harlé, 1997, Thrombosis and Haemostasis.

Factor V Leiden Homozygous Genotype and Pregnancy Outcomes

P. Morange, C. Biron-Andréani, Y. Gruel, 2009, Obstetrics and gynecology.

Long-Read Sequencing Identifies the First Retrotransposon Insertion and Resolves Structural Variants Causing Antithrombin Deficiency

Nicholas S. Gleadall, W. Ouwehand, P. Morange, 2022, Thrombosis and haemostasis.

Long-Read Sequencing Identi ﬁ es the First Retrotransposon Insertion and Resolves Structural Variants Causing Antithrombin De ﬁ ciency

Nicholas S. Gleadall, W. Ouwehand, P. Morange, 2022 .

The natural occurrence of human fibrinogen variants disrupting inter-chain disulfide bonds (AαCys36Gly, AαCys36Arg and AαCys45Tyr) confirms the role of N-terminal Aα disulfide bonds in protein assembly and secretion

P. Morange, P. de Mazancourt, J. Abgrall, 2011, Haematologica.

TFPI resistance related to inherited or acquired protein S deficiency.

P. Morange, C. Chapelle, P. Mismetti, 2012, Thrombosis research.

A rapid, easy, and scalable whole blood monocyte CD169 assay for outpatient screening during SARS-CoV-2 outbreak, and potentially other emerging disease outbreaks

P. Morange, J. Mege, M. Million, 2022, SAGE open medicine.

Fibrinogen, obesity and insulin resistance.

P. Morange, I. Juhan-vague, M. Alessi, 1999, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Juvenile temporal arteritis and activated protein C resistance

P. Morange, J. Serratrice, P. Disdier, 2004, Annals of the rheumatic diseases.

Anticorps antiphospholipides au cours d’une maladie de Gaucher. Discussion à propos d’un cas

P. Morange, L. Swiader, B. Granel, 2002 .

Fat Cell Function and Fibrinolysis

P. Morange, I. Juhan-vague, M. Alessi, 2000, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

Plasma Phospholipid Fatty Acids and Risk of Venous Thromboembolism: Mendelian Randomization Investigation

S. Larsson, P. Morange, M. Bruzelius, 2022, Nutrients.

Common susceptibility alleles are unlikely to contribute as strongly as the FV and ABO loci to VTE risk: results from a GWAS approach.

S. Heath, D. Trégouët, L. Tiret, 2009, Blood.

ABO blood group, glycosyltransferase activity and risk of venous thromboembolism.

D. Trégouët, P. Morange, J. Chiaroni, 2020, Thrombosis research.

ABO blood group, glycosyltransferase activity and risk of Venous Thrombosis

D. Trégouët, P. Morange, J. Chiaroni, 2020, bioRxiv.

Brief report KNG1 Ile581Thr and susceptibility to venous thrombosis

L. Letenneur, D. Trégouët, M. Lathrop, 2011 .

Factor XIIIV34L is not an additional genetic risk factor for venous thrombosis in Factor V Leiden carriers

P. Morange, I. Juhan-vague, D. Brunet, 2001 .

Lack of association between the 807 C/T polymorphism of glycoprotein Ia gene and post-treatment platelet reactivity after aspirin and clopidogrel in patients with acute coronary syndrome

P. Morange, M. Alessi, T. Cuisset, 2007, Thrombosis and Haemostasis.

Long-range epigenetic regulation is conferred by genetic variation located at thousands of independent loci

Mathieu Lemire, Steven Gallinger, Brent W Zanke, 2015, Nature Communications.

CD169 and CD64 could help differentiate bacterial from CoVID‐19 or other viral infections in the Emergency Department

A. Loundou, P. Morange, P. Michelet, 2021, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

CD64 and CD169 could help differentiate bacterial from viral infections in Emergency Department

A. Loundou, P. Morange, A. Loundou, 2020, medRxiv.

Antithrombin, protein C and protein S: Genome and transcriptome wide association studies identify 7 novel loci regulating plasma levels

D. A. Dobson, J. Pankow, D. Tregouet, 2022, medRxiv.

Clinical characteristics and laboratory testing of patients with suspected HIT: a survey on current practice in 11 university hospitals in France.

P. Morange, D. Desprez, A. Bidet, 2010, Thrombosis research.

Antiphosphatidylethanolamine Antibodies: New Pieces to the Puzzle of the Antiphospholipid Syndrome?

P. Morange, N. Bardin, C. Zaratzian, 2015 .

Very high TAFI antigen levels are associated with a lower risk of hard coronary events: the PRIME Study

P. Morange, I. Juhan-vague, 2003, Journal of thrombosis and haemostasis : JTH.

Association between TAFI antigen and Ala147Thr polymorphism of the TAFI gene and the angina pectoris incidence

A. Evans, D. Arveiler, G. Luc, 2003, Thrombosis and Haemostasis.

Association between TAFI antigen and Ala l47Thr polymorphism of the TAFI gene and the angina pectoris incidence

A. Evans, D. Arveiler, G. Luc, 2003 .

Contribution of anti-β2glycoprotein I IgA antibodies to the diagnosis of anti-phospholipid syndrome: potential interest of target domains to discriminate thrombotic and non-thrombotic patients.

William W. Cohen, P. Morange, P. Bongrand, 2014, Rheumatology.

Quantification of thrombin activatable fibrinolysis inhibitor (TAFI) gene polymorphism effects on plasma levels of TAFI measured with assays insensitive to isoform-dependent artefact

D. Tregouet, P. Morange, M. Alessi, 2005, Thrombosis and Haemostasis.

Role of the interferons in CD64 and CD169 expressions in whole blood: Relevance in the balance between viral‐ or bacterial‐oriented immune responses

P. Morange, Ines Ait Belkacem, P. Bourgoin, 2020, Immunity, inflammation and disease.

Toward Monocyte HLA-DR Bedside Monitoring: A Proof-of-Concept Study

P. Morange, T. Rimmele, F. Venet, 2020, Shock.

Germline variants in ETV 6 underlie reduced platelet formation , platelet dysfunction and increased levels of circulating CD 34 + progenitors

Kathleen, Franck, P. Morange, 2018 .

Title Page / Table of Contents / Preface

F. Sofi, R. Abbate, P. Morange, 2003, Pathophysiology of Haemostasis and Thrombosis.

Aprotinin administration and pulmonary embolism after aortic valve replacement.

P. Morange, F. Collart, A. Montcriol, 2008, Journal of cardiothoracic and vascular anesthesia.

Management of cardiovascular disease in haemophilia.

P. Morange, G. Cayla, H. Chambost, 2013, Thrombosis research.

Effects of insulin-like growth factor 1 in preventing acute coronary syndromes: the PRIME study.

D. Arveiler, G. Luc, J. Ruidavets, 2011, Atherosclerosis.

Genomic and phenotypic insights from an atlas of genetic effects on DNA methylation

Annelot M. Dekker, Walk, A. Caspi, 2021, Nature Genetics.

Macrothrombocytopenia and dense granule deficiency associated with FLI1 variants: ultrastructural and pathogenic features

Jean-François Deleuze, Robert Olaso, Anne Boland, 2017, Haematologica.

Genetics of Venous Thrombosis: update in 2015

D. Trégouët, P. Morange, P. Suchon, 2015, Thrombosis and Haemostasis.

Influence of coronary artery disease-associated genetic variants on risk of venous thromboembolism.

D. Trégouët, J. Odeberg, A. Syvänen, 2014, Thrombosis research.

Stroke genetics informs drug discovery and risk prediction across ancestries

Stephen R. Williams, Yan V. Sun, Y. J. Kim, 2022 .

A novel rare c.-39C>T mutation in the PROS1 5'UTR causing PS deficiency by creating a new upstream translation initiation codon.

D. Trégouët, P. Morange, C. Proust, 2020, Clinical science.

A Genome‐Wide Association Study for Venous Thromboembolism: The Extended Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium

Sebastian M. Armasu, A. Hofman, A. Uitterlinden, 2013, Genetic epidemiology.

A meta-analysis of 120 246 individuals identifies 18 new loci for fibrinogen concentration.

Lorna M. Lopez, Min A. Jhun, R. Marioni, 2016, Human molecular genetics.

Inborn errors of type I IFN immunity in patients with life-threatening COVID-19

Jacques Fellay, Agatha Schlüter, Aurora Pujol, 2020, Science.

Genetically defined elevated homocysteine levels do not result in widespread changes of DNA methylation in leukocytes

R. Marioni, L. Liang, C. Gieger, 2017, PloS one.

Robust validation of methylation levels association at CPT1A locus with lipid plasma levels1

D. Trégouët, P. Morange, F. Gagnon, 2014, Journal of Lipid Research.

What is currently known about the genetics of venous thromboembolism at the dawn of next generation sequencing technologies

D. Trégouët, P. Morange, 2018, British journal of haematology.

Risk assessment of venous thrombosis in families with known hereditary thrombophilia: the MARseilles‐NImes prediction model

D. Trégouët, W. Cohen, P. Morange, 2014, Journal of thrombosis and haemostasis : JTH.

Cerebral small vessel disease genomics and its implications across the lifespan

N. Eriksson, P. Matthews, M. Fornage, 2020, Nature Communications.

Assessment of platelet function on the routine coagulation analyzer Sysmex CS-2000i

P. Morange, M. Alessi, C. Frère, 2018, Platelets.

Peripartum bleeding management in a patient with CalDAG‐GEFI deficiency

P. Morange, P. Nurden, J. Gris, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

Human CalDAG-GEFI gene (RASGRP2) mutation affects platelet function and causes severe bleeding

D. Tregouet, F. Cambien, C. Perret, 2014, The Journal of experimental medicine.

SLC44A2 deficient mice have a reduced response in stenosis but not in hypercoagulability driven venous thrombosis

P. Morange, H. Versteeg, J. Cosemans, 2020, Journal of thrombosis and haemostasis : JTH.

Associations of autozygosity with a broad range of human phenotypes

May E. Montasser, Annelot M. Dekker, Blair H. Smith, 2019, Nature Communications.

Exclusive expression of transmembrane TNF-α in mice reduces the inflammatory response in early lipid lesions of aortic sinus

P. Morange, H. Portugal, I. Juhan-vague, 2004 .

Germline variants in ETV6 underlie reduced platelet formation, platelet dysfunction and increased levels of circulating CD34+ progenitors

W. Ouwehand, D. Trégouët, P. Morange, 2017, Haematologica.

Interleukin-6 Signaling Effects on Ischemic Stroke and Other Cardiovascular Outcomes

Sebastian M. Armasu, Andrew D. Johnson, James W. MacDonald, 2019, Circulation. Genomic and precision medicine.

Fibrinolytic function and coronary risk

P. Morange, I. Juhan-vague, Marie Christine Alessi, 1999, Current cardiology reports.

Overexpression of PAI-1 Does Not Affect Adipose Tissue Development in Mice on SFD

P. Morange, M. Alessi, D. Collen, 2002 .

DNA methylation age is associated with an altered hemostatic profile in a multiethnic meta-analysis.

Andrew D. Johnson, Min A. Jhun, C. Ward‐Caviness, 2018, Blood.

Direct oral anticoagulants and digestive bleeding: therapeutic management and preventive measures

P. Morange, C. Boustière, R. Benamouzig, 2017, Therapeutic advances in gastroenterology.

Human genetic and immunological determinants of critical COVID-19 pneumonia

Mark S. Anderson, P. Gregersen, J. Casanova, 2022, Nature.

Protein S Heerlen mutation heterozygosity is associated with venous thrombosis risk

X. Jouven, D. Trégouët, M. Germain, 2017, Scientific Reports.

A novel rare c. -39C>T mutation in the PROS1 5’UTR causing PS deficiency by creating a new upstream translation initiation codon and inhibiting the production of the natural protein

D. Trégouët, P. Morange, C. Proust, 2020, bioRxiv.

Protein Z plasma levels are not associated with the risk of coronary heart disease: the PRIME Study

P. Morange, I. Juhan-vague, 2004, Journal of thrombosis and haemostasis : JTH.

Relative Contribution of Lipids and Apolipoproteins to Incident Coronary Heart Disease and Ischemic Stroke: The PRIME Study

A. Evans, D. Arveiler, G. Luc, 2010, Cerebrovascular Diseases.

Testing for association with rare variants in the coding and non-coding genome: RAVA-FIRST, a new approach based on CADD deleteriousness score

G. Marenne, E. Génin, D. Trégouët, 2021, bioRxiv.

Thrombosis in central obesity and metabolic syndrome: Mechanisms and epidemiology

P. Morange, M. Alessi, 2013, Thrombosis and Haemostasis.

Genome-Wide Association Study for Circulating Tissue Plasminogen Activator Levels and Functional Follow-Up Implicates Endothelial STXBP5 and STX2

Scott M. Williams, Andrew D. Johnson, M. Fornage, 2014, Arteriosclerosis, thrombosis, and vascular biology.

Multiple Biomarkers for the Prediction of Ischemic Stroke: The PRIME Study

G. Luc, P. Amouyel, P. Morange, 2013, Arteriosclerosis, thrombosis, and vascular biology.

Multiethnic Meta-Analysis of Genome-Wide Association Studies in >100 000 Subjects Identifies 23 Fibrinogen-Associated Loci but No Strong Evidence of a Causal Association Between Circulating Fibrinogen and Cardiovascular Disease

Andrew D. Johnson, Lorna M. Lopez, C. Sudlow, 2013, Circulation.

Is Oxidative Stress an Emerging Player in the Thrombosis of Patients with Anti-Phosphatidylethanolamine Autoantibodies?

P. Morange, R. Guieu, J. Steinberg, 2022, Journal of clinical medicine.

Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting.

P. Morange, M. Alessi, T. Cuisset, 2006, Journal of the American College of Cardiology.

High post‐treatment platelet reactivity identified low‐responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome

P. Morange, M. Alessi, T. Cuisset, 2006, Journal of thrombosis and haemostasis : JTH.

Systemic chemokine levels, coronary heart disease, and ischemic stroke events

A. Evans, D. Arveiler, G. Luc, 2011, Neurology.

Elucidating mechanisms of genetic cross-disease associations at the PROCR vascular disease locus

Min A. Jhun, J. Danesh, R. Marioni, 2022, Nature Communications.

miR-421 and miR-30c Inhibit SERPINE 1 Gene Expression in Human Endothelial Cells

D. Trégouët, P. Morange, C. Proust, 2012, PloS one.

An artificial neural network approach integrating plasma proteomics and genetic data identifies PLXNA4 as a new susceptibility locus for pulmonary embolism

D. Trégouët, J. Odeberg, P. Morange, 2020, Scientific Reports.

Genome-Wide Association Transethnic Meta-Analyses Identifies Novel Associations Regulating Coagulation Factor VIII and von Willebrand Factor Plasma Levels

Andrew D. Johnson, C. Ward‐Caviness, M. Fornage, 2019, Circulation.

Genome-wide association study for circulating levels of PAI-1 provides novel insights into its regulation.

Scott M. Williams, Andrew D. Johnson, J. Danesh, 2012, Blood.

D. Tregouet, P. Morange, A. Gozzini, 2021, Clinical epigenetics.

A PRDX1 mutant allele causes a MMACHC secondary epimutation in cblC patients

W. Chung, M. Baumgartner, A. Montpetit, 2018, Nature Communications.

Plasminogen activator inhibitor‐1, inflammation, obesity, insulin resistance and vascular risk

P. Morange, I. Juhan-vague, M. Alessi, 2003, Journal of thrombosis and haemostasis : JTH.

A granulocytic signature identifies COVID-19 and its severity

P. Morange, D. Olive, J. Mege, 2020, The Journal of infectious diseases.

Haemostatic Factors and the Risk of Cardiovascular Death in Patients With Coronary Artery Disease: The AtheroGene Study

H J Rupprecht, L Tiret, R. Schnabel, 2006, Arteriosclerosis, thrombosis, and vascular biology.

Association of Plasminogen Activator Inhibitor (PAI)-1 (SERPINE1) SNPs With Myocardial Infarction, Plasma PAI-1, and Metabolic Parameters: The HIFMECH Study

M. Margaglione, S. Humphries, D. Tregouet, 2007, Arteriosclerosis, thrombosis, and vascular biology.

[Bilateral adrenal hemorrhage under apixaban in primary antiphospholipid syndrome].

P. Morange, B. Faucher, J. Harlé, 2020, La Revue de medecine interne.

Identification of polymorphisms in the promoter and the 3' region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled.

L. Tiret, P. Morange, M. Alessi, 2001, Blood.

A meta-analysis of genome-wide association studies identifies ORM1 as a novel gene controlling thrombin generation potential.

F. Cambien, L. Letenneur, D. Trégouët, 2014, Blood.

Fine mapping of quantitative trait nucleotides underlying thrombin-activatable fibrinolysis inhibitor antigen levels by a transethnic study.

D. Tregouet, L. Tiret, P. Morange, 2006, Blood.

Ala147Thr and C+1542G Polymorphisms in the TAFI Gene Are not Asssociated with a Higher Risk of Venous Thrombosis in FV Leiden Carriers

P. Morange, V. Nicaud, I. Juhan-vague, 2001, Thrombosis and Haemostasis.

Intravenous immunoglobulin in patients with acquired Von Willebrand syndrome: A single referral centre experience

P. Morange, J. Harlé, M. Ebbo, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

Bayesian network analysis of plasma microRNA sequencing data in patients with venous thrombosis

D. Trégouët, C. Perret, P. Morange, 2020, European heart journal supplements : journal of the European Society of Cardiology.

Contribution of novel biomarkers to incident stable angina and acute coronary syndrome: the PRIME Study.

A. Evans, D. Arveiler, G. Luc, 2008, European heart journal.

A rare coding mutation in the MAST2 gene causes venous thrombosis in a French family with unexplained thrombophilia: The Breizh MAST2 Arg89Gln variant

D. Trégouët, P. Morange, C. Proust, 2020, medRxiv.

Association of ABO haplotypes with the risk of venous thrombosis: impact on disease risks estimation.

Andrew D. Johnson, D. Chasman, D. Trégouët, 2020, Blood.

Acquired inhibitor of thrombin associated with an ulcerative colitis

P. Morange, J. Serratrice, P. Disdier, 2000, American journal of hematology.

KNG1 Ile581Thr and susceptibility to venous thrombosis.

William W. Cohen, Lorna M. Lopez, L. Letenneur, 2011, Blood.

Cross-Ancestry Investigation of Venous Thromboembolism Genomic Predictors

Sebastian M. Armasu, Andrew D. Johnson, A. Reiner, 2022, medRxiv.

Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study.

P. Morange, M. Alessi, T. Cuisset, 2008, JACC. Cardiovascular interventions.

Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome.

P. Morange, M. Alessi, T. Cuisset, 2008, The American journal of cardiology.

No Evidence for Genome-Wide Interactions on Plasma Fibrinogen by Smoking, Alcohol Consumption and Body Mass Index: Results from Meta-Analyses of 80,607 Subjects

Lorna M. Lopez, Audrey Y. Chu, M. Fornage, 2014, PloS one.

Prevention of thrombotic risk in hospitalized patients with COVID-19 and hemostasis monitoring

P. Morange, S. Susen, S. Testa, 2020, Critical Care.

Association of vitronectin and plasminogen activator inhibitor-1 levels with the risk of metabolic syndrome and type 2 diabetes mellitus Results from the D.E.S.I.R. prospective cohort

D. Tregouet, B. Balkau, P. Morange, 2022 .

Economic Analysis of Thrombo inCode, a Clinical–Genetic Function for Assessing the Risk of Venous Thromboembolism

P. Morange, J. Souto, E. Salas, 2015, Applied Health Economics and Health Policy.

Economic Analysis Of Thrombo Incode, A Clinical-Genetic Function For Assessing The Risk Of Venous Thromboembolism.

P. Morange, J. Souto, E. Salas, 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Adipocytokines and the risk of coronary heart disease in healthy middle aged men: the PRIME Study

D. Arveiler, G. Luc, P. Amouyel, 2010, International Journal of Obesity.

Hemostatic Abnormalities in Diabetes

P. Morange, M. Alessi, I. Juhan-vague, 2003 .

The insulin resistance syndrome: implications for thrombosis and cardiovascular disease

P. Morange, M. Alessi, I. Juhan-vague, 2002, Pathophysiology of Haemostasis and Thrombosis.

Plasminogen activator inhibitor 1, transforming growth factor-beta1, and BMI are closely associated in human adipose tissue during morbid obesity.

P. Morange, D. Bastelica, M. Alessi, 2000, Diabetes.

Genome-Wide Association Study for Circulating Tissue Plasminogen Activator Levels and Functional Follow-Up Implicates Endothelial STXBP 5 and STX 2

Scott M. Williams, Andrew D. Johnson, O. Franco, 2014 .

Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome.

P. Morange, M. Alessi, T. Cuisset, 2007, Thrombosis research.

Polymorphism A36G of the tumor necrosis factor receptor 1 gene is associated with PAI-1 levels in obese women

P. Morange, M. Poggi, D. Bastelica, 2006, Thrombosis and Haemostasis.

Genetic variation in F3 (tissue factor) and the risk of incident venous thrombosis: meta‐analysis of eight studies

D. Chasman, P. Morange, J. Heit, 2012, Journal of thrombosis and haemostasis : JTH.

Theme 2: Epidemiology, Biomarkers, and Imaging of Venous Thromboembolism (and postthrombotic syndrome).

P. Morange, N. Mackman, M. Huisman, 2015, Thrombosis research.

Assessing the causal relationship between obesity and venous thromboembolism through a Mendelian Randomization study

P. Ridker, D. Chasman, F. Grodstein, 2017, Human Genetics.

TLR4/Asp299Gly, CD14/C-260T, plasma levels of the soluble receptor CD14 and the risk of coronary heart disease: The PRIME Study

D. Arveiler, G. Luc, L. Tiret, 2004, European Journal of Human Genetics.

Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: the BIGPRO1 Study. Biguanides and the Prevention of the Risk of Obesity.

P. Morange, M. Charles, P. Vague, 1998, Diabetes care.

Platelet reactivity in diabetic patients undergoing coronary stenting for acute coronary syndrome treated with clopidogrel loading dose followed by prasugrel maintenance therapy.

A. Loundou, P. Morange, M. Alessi, 2013, International journal of cardiology.

Genetic determined low response to thienopyridines is associated with higher systemic inflammation in smokers.

G. Siest, P. Morange, M. Stathopoulou, 2015, Pharmacogenomics.

Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19

Andrew J. Oler, Eglantine Ferrand Devouge, P. Gregersen, 2023, Genome Medicine.

SARS-CoV-2 spike protein induces a differential monocyte activation that may contribute to age bias in COVID-19 severity

P. Morange, Jean-Marc Busnel, I. Arnoux, 2022, Scientific Reports.

Low-grade inflammation may play a role in the etiology of the metabolic syndrome in patients with coronary heart disease: the HIFMECH study.

M. Margaglione, S. Humphries, E. Hawe, 2004, Metabolism: clinical and experimental.

Association of ABO blood groups with venous thrombosis recurrence in middle-aged patients: insights from a weighted Cox analysis dedicated to ambispective design

H. Jacqmin-Gadda, D. Trégouët, P. Morange, 2023, BMC Medical Research Methodology.

A Platelet Function Modulator of Thrombin Activation Is Causally Linked to Cardiovascular Disease and Affects PAR4 Receptor Signaling.

Andrew D. Johnson, V. Salomaa, P. Elwood, 2020, American journal of human genetics.

Minor allele of the factor V K858R variant protects from venous thrombosis only in non-carriers of factor V Leiden mutation

D. Trégouët, M. Germain, P. Amouyel, 2019, Scientific Reports.

C4BPB/C4BPA is a new susceptibility locus for venous thrombosis with unknown protein S-independent mechanism: results from genome-wide association and gene expression analyses followed by case-control studies.

L. Almasy, A. Buil, S. Blankenberg, 2010, Blood.

Off-label use of prasugrel in stable coronary artery disease is associated with greater degree of platelet inhibition compared with use after acute coronary syndrome.

P. Morange, M. Alessi, G. Bonnet, 2013, International journal of cardiology.

Recent advances in the pharmacogenetics of clopidogrel

P. Morange, M. Alessi, T. Cuisset, 2012, Human Genetics.

Catastrophic Arterial Reactivity During Primary Antiphospholipid Syndrome

P. Morange, J. Serratrice, P. Disdier, 1999, Angiology.

Caution in Interpreting Results from Imputation Analysis When Linkage Disequilibrium Extends over a Large Distance: A Case Study on Venous Thrombosis

F. Cambien, L. Letenneur, D. Trégouët, 2012, PloS one.

Combined segregation-linkage analysis of plasma thrombin activatable fibrinolysis inhibitor (TAFI) antigen levels with TAFI gene polymorphisms

D. Tregouet, L. Tiret, P. Morange, 2001, Human Genetics.

Prospective analysis of factor XI deficiencies in the Marseilles area identified four novel mutations among 12 consecutive unrelated families

P. Morange, P. de Mazancourt, C. Frère, 2009, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

The factor XII -4C>T variant and risk of common thrombotic disorders: A HuGE review and meta-analysis of evidence from observational studies.

D. Tregouet, P. Morange, A. Tuite, 2011, American journal of epidemiology.

activatable fibrinolysis inhibitor antigen levels by a trans-ethnic study Fine mapping of quantitative trait nucleotides underlying thrombin

D. Trégouët, L. Tiret, P. Morange, 2013 .

Thr325IIe polymorphism of the TAFI gene does not influence the risk of myocardial infarction.

P. Morange, I. Juhan-vague, C. Frere, 2002, Blood.

FGL1 as a modulator of plasma D‐dimer levels: Exome‐wide marker analysis of plasma tPA, PAI‐1, and D‐dimer

Andrew D. Johnson, M. Nalls, T. Hansen, 2021, Journal of thrombosis and haemostasis : JTH.

Polymorphisms of the tumor necrosis factor-alpha (TNF) and the TNF-alpha converting enzyme (TACE/ADAM17) genes in relation to cardiovascular mortality: the AtheroGene study

D. Tregouet, S. Blankenberg, D. Trégouët, 2008, Journal of Molecular Medicine.

Perioperative thromboprophylaxis in severely obese patients undergoing bariatric surgery: insights from a French national survey.

P. Morange, C. Frère, O. Ziegler, 2017, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.

Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19

Andrew J. Oler, Eglantine Ferrand Devouge, P. Gregersen, 2023, Genome Medicine.

Interaction between the C-260T polymorphism of the CD14 gene and the plasma IL-6 concentration on the risk of myocardial infarction: the HIFMECH study.

M. Margaglione, S. Humphries, E. Hawe, 2005, Atherosclerosis.

Explainable Artificial Neural Network for Recurrent Venous Thromboembolism Based on Plasma Proteomics

Misbah Razzaq, Louisa Goumidi, Maria-Jesus Iglesias, 2021, CMSB.

Cryoglobulinemia vasculitis following intravesical instillations of bacillus Calmette-Guerin.

P. Morange, J. Serratrice, P. Disdier, 2004, Clinical and experimental rheumatology.

Adipose Tissue Expression of Gelatinases in Mouse Models of Obesity

P. Morange, H. Lijnen, A. Mertens, 2001, Thrombosis and Haemostasis.

A large‐scale exome array analysis of venous thromboembolism

Andrew D. Johnson, W. Guan, A. Reiner, 2019, Genetic epidemiology.

TAFI gene haplotypes, TAFI plasma levels and future risk of coronary heart disease: the PRIME Study

D. Tregouet, D. Arveiler, G. Luc, 2005, Journal of thrombosis and haemostasis : JTH.

Molecular characterization of a novel mutation in the factor XIII a subunit gene associated with a severe defect: importance of prophylactic substitution.

P. Morange, C. Boucly, P. de Mazancourt, 2009, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Molecular characterization of a novel mutation in the factor XIII A subunit gene associated with a severe defect and an adulthood diagnosis

P. Morange, P. de Mazancourt, C. Frère, 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

Modelling of time-to-events in an ambispective study: illustration with the analysis of ABO blood groups on venous thrombosis recurrence

H. Jacqmin-Gadda, D. Trégouët, P. Morange, 2021, medRxiv.

Cerebral Venous Thrombosis: Clinical, Radiological, Biological, and Etiological Characteristics of a French Prospective Cohort (FPCCVT)—Comparison With ISCVT Cohort

P. Morange, F. Viader, T. Moulin, 2021, Frontiers in Neurology.

Two SERPINC1 variants affecting N-glycosylation of Asn224 cause severe thrombophilia not detected by functional assays

D. Trégouët, P. Morange, J. Deleuze, 2022, Blood.

CD11b+ leukocyte microparticles are associated with high‐risk angiographic lesions and recurrent cardiovascular events in acute coronary syndromes

P. Morange, T. Cuisset, J. Bonnet, 2011, Journal of thrombosis and haemostasis : JTH.

074 Comparison of rosuvastatin and atorvastatin on clopidogrel response and lipidic and inflammatory parameters after coronary stenting for acute coronary syndrome

P. Morange, T. Cuisset, J. Bonnet, 2012 .

Epimutations in both the TESK2 and MMACHC promoters in the Epi-cblC inherited disorder of intracellular metabolism of vitamin B12

M. Baumgartner, D. Trégouët, P. Morange, 2022, Clinical epigenetics.

Severe thrombophilia in a factor V‐deficient patient homozygous for the Ala2086Asp mutation (FV Besançon)

P. Morange, K. Wichapong, M. Poggi, 2021, Journal of thrombosis and haemostasis : JTH.

Elevated plasma complement factor H related 5 protein is associated with venous thromboembolism

T. Renné, D. Trégouët, F. Edfors, 2023, Nature communications.

C 4 BPB / C 4 BPA is a new susceptibility locus for venous thrombosis with unknown protein S – independent mechanism : results from genome-wide association and gene expression analyses followed by case-control studies

L. Almasy, A. Buil, S. Blankenberg, 2010 .

DA Combination of Single Nucleotide Polymorphisms is Associated with the Interindividual Variability of Cholesterol Bioavailability in Healthy Adult Males.

P. Morange, D. Lairon, M. Alessi, 2020, Molecular nutrition & food research.

Safety and effectiveness of the association ezetimibe-statin (E-S) versus high dose rosuvastatin after acute coronary syndrome: the SAFE-ES study.

P. Morange, M. Alessi, G. Bonnet, 2014, Annales de cardiologie et d'angeiologie.

Associations of autozygosity with a broad range of human phenotypes

May E. Montasser, Annelot M. Dekker, Blair H. Smith, 2019, Nature Communications.

The reactivity of paired plasma and serum samples are comparable in the anticardiolipin and anti-b2-glycoprotein-1

M. Yamakuchi, P. Amouyel, P. Morange, 2006 .

Protein S deficiency: different biological phenotypes according to the assays used.

P. Morange, M. Alessi, D. Borgel, 1998, Thrombosis and haemostasis.

A Three-generation Family Presenting Five Cases of Homozygosity for the 20210 G to A Prothrombin Variant

P. Morange, M. Alessi, I. Juhan-vague, 1998, Thrombosis and Haemostasis.

Polymorphisms of the lamina maturation pathway and their association with the metabolic syndrome: the DESIR prospective study

D. Trégouët, P. Morange, M. Marre, 2010, Journal of Molecular Medicine.

Antithrombin, Protein C, and Protein S: Genome and Transcriptome-Wide Association Studies Identify 7 Novel Loci Regulating Plasma Levels

J. Pankow, D. Trégouët, C. Sitlani, 2023, Arteriosclerosis, thrombosis, and vascular biology.

Resistance to Activated Protein C – Diagnostic Strategy in a Laboratory of Haemostasis

P. Gallian, P. Morange, M. Alessi, 1995, Thrombosis and Haemostasis.

First case of a human RASGRP2 mutation affecting Rap1 activation in platelets and causing severe bleeding.

F. Cambien, D. Trégouët, C. Perret, 2014 .

High-Dimensional Multi-Block Analysis of Factors Associated with Thrombin Generation Potential

David Alexandre, Rodolphe Thiébaut, Jérôme Saracco, 2019, 2019 IEEE 32nd International Symposium on Computer-Based Medical Systems (CBMS).

Lack of effect of chronic kidney disease on clopidogrel response with high loading and maintenance doses of clopidogrel after Acute Coronary Syndrome.

P. Morange, M. Alessi, T. Cuisset, 2010, Thrombosis research.

Dabigatran Level Before Reversal Can Predict Hemostatic Effectiveness of Idarucizumab in a Real-World Setting

P. Morange, L. Bertoletti, E. de Raucourt, 2020, Frontiers in Medicine.

No Evidence for Genome-Wide Interactions on Plasma Fibrinogen by Smoking, Alcohol Consumption and Body Mass Index: Results from Meta-Analyses of 80,607 Subjects

Lorna M. Lopez, Audrey Y. Chu, M. Fornage, 2014, PloS one.

No Evidence for Genome-Wide Interactions on Plasma Fibrinogen by Smoking, Alcohol Consumption and Body Mass Index Baumert, Jens

Lorna M. Lopez, Audrey Y. Chu, M. Fornage, 2022 .

Recent advances in the pharmacogenetics of clopidogrel

P. Morange, M. Alessi, T. Cuisset, 2011, Human Genetics.

Cross-Ancestry Investigation of Venous Thromboembolism Genomic Predictors

Sebastian M. Armasu, Andrew D. Johnson, A. Reiner, 2022, Circulation.

Meta-analysis of 65,734 individuals identifies TSPAN15 and SLC44A2 as two susceptibility loci for venous thromboembolism.

P. Deloukas, P. Ridker, D. Chasman, 2015, American journal of human genetics.

Thrombosis in central obesity and metabolic syndrome: Mechanisms and epidemiology

P. Morange, M. Alessi, 2013, Thrombosis and Haemostasis.

Current knowledge on the genetics of incident venous thrombosis

D. Trégouët, P. Morange, 2013, Journal of thrombosis and haemostasis : JTH.

Ile581Thr and susceptibility to venous thrombosis KNG1

Lorna M. Lopez, L. Letenneur, J. Lambert, 2013 .

[Evaluation of an "Emergency Thrombosis" care system in a university-hospital department of general emergencies].

P. Morange, J. Deharo, G. Sarlon-Bartoli, 2019, Journal de medecine vasculaire.

Edinburgh Research Explorer Genetic Associations for Activated Partial Thromboplastin Time and Prothrombin Time, Their Gene Expression Profiles, and Risk of Coronary Artery Disease Genetic Associations for Activated Partial Thromboplastin Time and Prothrombin Time, Their Gene Expression Profiles, an

Lorna M. Lopez, I. Deary, E. Boerwinkle, 2022 .

Abstract 090: Slc44a2 Deficient Mice Exhibit Less Severity of Thrombosis in a Stenosis Model of Deep Vein Thrombosis

P. Morange, B. Vlijmen, J. Tilburg, 2018 .

Publisher Correction: Stroke genetics informs drug discovery and risk prediction across ancestries

Sebastian M. Armasu, Andrew D. Johnson, Stephen R. Williams, 2022, Nature.

Clopidogrel response: head-to-head comparison of different platelet assays to identify clopidogrel non responder patients after coronary stenting.

P. Morange, M. Alessi, T. Cuisset, 2010, Archives of cardiovascular diseases.

FOCUS ISSUE: CARDIAC INTERVENTION Benefit of a 600-mg Loading Dose of Clopidogrel on Platelet Reactivity and Clinical Outcomes in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome Undergoing Coronary Stenting

P. Morange, M. Alessi, T. Cuisset, 2006 .

Stroke genetics informs drug discovery and risk prediction across ancestries

Sebastian M. Armasu, Laurent F. Thomas, J. Danesh, 2022, Nature.